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1. Introduction
Despite multiple efforts in development of novel therapies,
bringing novel drugs to the market is a costly and time-consuming
process that is coupled with great risks of failure. In many cases the
candidate substance does not reach the patients due to its side
effects, which are in turn the product of the off–target interactions.
Virtually any small molecule has at least several interactors among
tens of thousands of macromolecules present in our bodies.
Normally undesirable, such interactions of approved drugs with
known toxicity proﬁles are sometimes of a potential great value as
they might be useful for treatment of other diseases, resulting in
quick and low-cost repositioning of the drug. Consequently, many
researchers are searching for novel applications of substances that
have already passed the ﬁlter of clinical trials. To-date these efforts
resulted in the ‘‘second life’’ of 22 drugs [1]. In many cases novel
ﬁelds of drug application are unexpected, such as the notorious
case of sildaneﬁl (Viagra) [2] promoted from a poor remedy against
hypertension and angina to the rescue for erectile dysfunction; or a
less known case of thalidomide, leaping from the dangerous (and
later prohibited) drug against morning sickness in pregnant
women to the novel and effective anti-myeloma treatment [3].
Wnt-initiated signal transduction cascades play major roles in
the control of cell fate, proliferation and migration during
developmental stages of organisms but remain relatively silent
in healthy adults. Improper re-activation of the Wnt signaling
underlies multiple disorders, most notably cancers [4]. These
factors make the Wnt-controlled cascades pharmacologically
relevant focusing the efforts of many researchers on the
development of novel therapies targeting their components.
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A B S T R A C T
Research on existing drugs often discovers novel mechanisms of their action and leads to the expansion
of their therapeutic scope and subsequent remarketing. The Wnt signaling pathway is of the immediate
therapeutic relevance, as it plays critical roles in cancer development and progression. However, drugs
which disrupt this pathway are unavailable despite the high demand. Here we report an attempt to
identify antagonists of the Wnt–FZD interaction among the library of the FDA-approved drugs. We
performed an in silico screening which brought up several potential antagonists of the ligand-receptor
interaction. 14 of these substances were tested using the TopFlash luciferase reporter assay and four of
them identiﬁed as active and speciﬁc inhibitors of the Wnt3a-induced signaling. However, further
analysis through GTP-binding and b-catenin stabilization assays showed that the compounds do not
target the Wnt-FZD pair, but inhibit the signaling at downstream levels. We further describe the
previously unknown inhibitory activity of an anti-leprosy drug clofazimine in the Wnt pathway and
provide data demonstrating its efﬁciency in suppressing growth of Wnt-dependent triple-negative
breast cancer cells. These data provide a basis for further investigations of the efﬁciency of clofazimine in
treatment of Wnt-dependent cancers.
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